CanSino Wins Argentine Approval for Menhycia Vaccine as Global Push Accelerates

An announcement from CanSino Biologics, Inc. Class H ( (HK:6185) ) is now available.

CanSino Biologics said its ACYW135 meningococcal polysaccharide conjugate vaccine, marketed as Menhycia, has received a drug registration certificate from Argentina’s health authority. The vaccine is already approved in China for children from three months to just under seven years old, where trials have shown favorable safety and immunogenicity profiles, and the company is preparing a supplemental application to extend its indicated age range up to 59 years.

Management described the Argentine approval as a milestone in Menhycia’s internationalization, boosting the company’s global recognition and supporting its broader overseas strategy. CanSino plans to leverage technology transfer and the supply of intermediates and finished products to build partnerships in Latin America and other priority regions, while cautioning that the timing and scale of Argentine sales will depend on demand in the approved population.

The most recent analyst rating on (HK:6185) stock is a Buy
with a HK$64.00 price target.
To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock,
see the HK:6185 Stock Forecast page.